



Presentation of Donesta[®] Phase 3 Topline Efficacy Results at the 20th ISGE World Congress

Liege, Belgium, 12 May 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, announces that several presentations focusing on therapeutic opportunities for estetrol (E4) will be held at the 20th World Congress of the International Society of Gynecological Endocrinology (ISGE)¹ taking place from 11-14 May 2022 in Florence, Italy. A selection of these presentations will be made available in the coming days in the investors section of the company's website.

Graham Dixon, CSO Mithra Women's Health, commented: *"We are very pleased to present for the first time the Phase 3 positive topline results of our product candidate Donesta[®] in this major scientific conference. The wide range of presentations on E4 scheduled during this congress demonstrates the growing interest of the scientific community for a new estrogen displaying a broad potential and a unique safety profile, both in women's health and in key therapeutic areas such as neuroprotection."*

E4 perspectives in women's health and beyond

On Thursday 12th May (09:45-11:15), the following lectures will present E4 most recent development results in women's health and beyond in a dedicated scientific symposium titled *"E4: a landmark in the making? Before and beyond reproductive age: new therapeutic opportunities for E4?"*.

- Prof. Amanda Black, Ottawa Hospital, Canada, will present the Phase 3 positive topline results of Donesta[®], Mithra's next generation orally-administrated estetrol (E4)-based hormone therapy product candidate;
- Prof. Jonathan Douxfils, University of Namur, Belgium, will expose recent clinical evidence on E4 safety profile in coagulation;
- Prof. Pauline Maki, University of Illinois, Chicago, USA, will detail the effect of estrogens in optimizing cognition and brain health at midlife and beyond;
- Pierre Gressens, INSERM, Paris, France, will present recent developments with E4 for protection in perinatal brain damage, showing for the first time induced neuroprotective activity in prematurity encephalopathy and opening additional avenues of research to assess E4 broader neuroprotective activity.

¹ The scientific program is available on the [ISGE website](#).

E4 new vascular unique profile

On Thursday 12th May (14:45-16:15), Prof. Jean-François Arnal, INSERM, Toulouse France, will give an presentation on the different vascular effects of estrogens according to age. His research shows in a non clinical model that E4 can protect the blood vessels integrity irrespective of aging to the contrary of other commonly used estrogens.

On Thursday May 12th (11:45-13:15), additional new research on E4 vascular profile will be presented by Ms. Laure Morimont, PharmD ,University of Namur. The new data demonstrate that E4 in combination with DRSP (Mithra's contraceptive pill Estelle®), could have a low risk of Venous Thromboembolism (VTE) even in comparison with second generation of combined oral contraceptives.

E4 in contraception

On Friday 13th May (08:30- 09:30), Prof. Jean-Michel Foidart, University of Liège, Belgium, will present new analyses showing high continuation rates in contraception observed with E4 in association with DRSP.

For more information, please contact:

Benoît Mathieu (IRO) : +32 473 35 80 18 - investorrelations@mithra.com

Maud Vanderthommen (Press) : +32 473 58 61 04 – press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle®, Mithra is now focusing on its second product Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. www.mithra.com

Donesta® is a registered trademark of Mithra Pharmaceuticals or one of its affiliates.

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.



News
Alerts

Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media :

[LinkedIn](#) • [Twitter](#) • [Facebook](#)